Keywords: doripenem, fares, well, vs, np, vap, health

J&J's doripenem fares well vs NP and VAP

Article | 01 October 2007

US health care major Johnson & Johnson's investigational antibiotic doripenem was found to clinically cure 81% of patients with nosocomial pneumonia, and 68% ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Johnson & Johnson

Shionogi

Go to company listing

Related Drugs

Nystatin

Go to drug listing